Biovitrum AB (publ) makes public a prospectus supplement
The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the Australia, Hong Kong, Japan, Canada, Switzerland, Singapore, South Africa or the United States.
Biovitrum AB (publ) (”Biovitrum”) has today made public a supplement to the previously published prospectus pertaining to the rights issue and the admission to trading of shares in Biovitrum. The prospectus supplement contains Biovitrum's press release from December 21, 2009 regarding AstraZenecas acquisition of all Biovitrum's rights to a discovery-stage research programme aimed at treating obesity and Biovitrum's press release from December 15, 2009 regarding that Biovitrum advances novel factor VIII long-acting hemophilia A therapy into clinical trials.The prospectus supplement is available at the Swedish Financial Supervisory Authority's website (www.fi.se), Biovitrum's website (www.biovitrum.com), Carnegie Investment Bank AB's website (www.carnegie.se), ABG Sundal Collier AB's website (www.abgsc.com) and Handelsbanken Capital Market's website (www.handelsbanken.se/aktuellaerbjudanden). Right of withdrawal Those investors who have applied for or in any other manner consented to purchase or subsribe for securities covered by the rights issue before the publication of the prospectus supplement are entitled to withdraw their registration until and including January 5, 2010 (i.e. five working days from the publication of the prospectus supplement).Such withdrawal must be submitted in writing to Carnegie Investment Bank AB no later than 5.00 pm CET on the last day for withdrawal as stated above. If the subscription was submitted through a nominee the withdrawal should be made through the nominee according to its instructions. Subscriptions that are not withdrawn will remain binding and those subscribers who wish to remain as subscribers do not need to take any further action. For further information, please contact: Erik Kinnman, EVP Investor Relations Biovitrum Phone: +46 73 422 15 40 erik.kinnman@biovitrum.com About Biovitrum Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions.Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. Biovitrum has revenues of approximately SEK 1.2 billion and approximately 400 employees (prior to the acquisition of Swedish Orphan International Holding AB). Biovitrum's head office is located in Sweden and the share is listed on the NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com. Important notice The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore. The information in this press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States.The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “Securities Act”). The securities mentioned herein may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States. The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever.Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions. The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act.The information was published at 2: p.m. CET on December 23, 2009.